These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7601199)

  • 1. Sulphydryl group control of sodium-lithium countertransport kinetics: a membrane protein control abnormality in essential hypertension.
    Thomas TH; Rutherford PA; West IC; Wilkinson R
    Eur J Clin Invest; 1995 Apr; 25(4):235-40. PubMed ID: 7601199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of erythrocyte Na+/Li+ countertransport kinetics by two types of thiol group.
    Thomas TH; West IC; Wilkinson R
    Biochim Biophys Acta; 1995 May; 1235(2):317-22. PubMed ID: 7756341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiol protein defect in sodium-lithium countertransport in subset of essential hypertension.
    Mead P; Wilkinson R; Thomas TH
    Hypertension; 1999 Dec; 34(6):1275-80. PubMed ID: 10601130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms and erythrocyte sodium-lithium countertransport in essential hypertension.
    Tournoy KG; Delanghe JR; Duprez DA; De Buyzere ML; Verbeeck RM; Vergauwe DA; Leroux-Roels GG; Clement DL
    Clin Chim Acta; 1996 Nov; 255(1):39-55. PubMed ID: 8930412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma lipids affect maximum velocity not sodium affinity of human sodium-lithium countertransport: distinction from essential hypertension.
    Rutherford PA; Thomas TH; Laker MF; Wilkinson R
    Eur J Clin Invest; 1992 Nov; 22(11):719-24. PubMed ID: 1478240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiol group control of sodium-lithium countertransport kinetics in uraemia: evidence of a membrane abnormality affected by haemodialysis.
    Rutherford PA; Thomas TH; O'Kelly J; West IC; Wilkinson R
    Nephron; 1996; 72(2):184-8. PubMed ID: 8684524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Na-Li countertransport kinetics in the relatives of hypertensive patients with abnormal Na-Li countertransport activity.
    Rutherford PA; Thomas TH; Wilkinson R
    Biochem Mol Med; 1997 Oct; 62(1):106-12. PubMed ID: 9367806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered membrane microviscosity in essential hypertension: relationship with family history of hypertension and sodium-lithium countertransport activity.
    Carr SJ; Sikand K; Moore D; Norman RI
    J Hypertens; 1995 Jan; 13(1):139-46. PubMed ID: 7759844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal effect of thiol groups on erythrocyte Na/Li countertransport kinetics in adult polycystic kidney disease.
    Vareesangthip K; Thomas TH; Wilkinson R
    Nephrol Dial Transplant; 1995 Dec; 10(12):2219-23. PubMed ID: 8808214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-lithium countertransport kinetics in IgA nephropathy: relation to plasma lipids and renal impairment.
    Ho KK; Thomas TH; Rutherford PA; Wilkinson R
    Nephron; 1995; 69(4):391-6. PubMed ID: 7777102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal kinetics of erythrocyte sodium lithium countertransport in patients with diabetic nephropathy in Thailand.
    Vareesangthip K; Panthongdee W; Shayakul C; Nitiyanant W; Ong-Aj-Yooth L
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S48-53. PubMed ID: 17044454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-lithium countertransport and the Gly460-->Trp alpha-adducin polymorphism in essential hypertension.
    Mead PA; Harvey JN; Rutherford PA; Leitch H; Thomas TH
    Clin Sci (Lond); 2005 Mar; 108(3):231-6. PubMed ID: 15554870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Na/Li countertransport abnormalities in type 1 diabetes with and without nephropathy are familial.
    Mead PA; Wilkinson R; Thomas TH
    Diabetes Care; 2001 Mar; 24(3):527-32. PubMed ID: 11289480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiol group modulation of sodium-lithium countertransport kinetics in diabetic nephropathy.
    Jones SC; Thomas TH; Marshall SM
    Diabetologia; 1997 Sep; 40(9):1079-84. PubMed ID: 9300245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the response of erythrocyte sodium-lithium countertransport to inhibitors.
    Rutherford PA; Thomas TH; Wilkinson R
    Biochem Med Metab Biol; 1993 Apr; 49(2):270-3. PubMed ID: 8484966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversies surrounding erythrocyte sodium-lithium countertransport.
    Hardman TC; Lant AF
    J Hypertens; 1996 Jun; 14(6):695-703. PubMed ID: 8793691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catamenial variations in erythrocyte sodium-lithium countertransport and blood pressure.
    Adebayo GI; Hemeryck L; Hall M; Gasparro D; Sinnott M; Feely J
    Clin Sci (Lond); 1997 Jul; 93(1):29-34. PubMed ID: 9279200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher urinary albumin excretion is associated with abnormal erythrocyte Na(+)/Li(+) countertransport (SLC) in non-modulating essential hypertensives and offspring of hypertensive parents.
    Sánchez RA; Giannone C; Masnatta LD; Baglivo HP; Ramírez AJ
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S128-32. PubMed ID: 11986910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal thiol reactivity of tropomyosin in essential hypertension and its association with abnormal sodium-lithium countertransport kinetics.
    Watkins SL; West IC; Wilkinson R; Thomas TH
    J Hypertens; 2001 Mar; 19(3):485-93. PubMed ID: 11288819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrocyte Na(+)-Li+ countertransport in essential hypertension: correlation with membrane lipids levels.
    Villar J; Montilla C; Muñiz-Grijalvo O; Muriana FG; Stiefel P; Ruiz-Gutiérrez V; Carneado J
    J Hypertens; 1996 Aug; 14(8):969-73. PubMed ID: 8884551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.